valsartan has been researched along with Glucose Intolerance in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 17 (89.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brancati, FL; Califf, RM; Chatterjee, R; Edelman, D; Svetkey, L; Thomas, L | 1 |
| Califf, RM; Chiang, FT; Giles, TD; Haffner, SM; Holman, RR; Mazzone, T; McMurray, JJ; Preiss, D; Rutten, GE; Standl, E; Sun, JL; Thomas, LE; Tognoni, G | 1 |
| Bethel, MA; Califf, RM; Chang, F; Disertori, M; Giles, TD; Haffner, SM; Holman, RR; Latini, R; Maggioni, AP; McMurray, JJ; Rutten, GE; Standl, E; Staszewsky, L; Sun, JL; Thomas, L; Tognoni, G | 1 |
| Bethel, MA; Califf, RM; Charbonnel, B; Diem, P; Haffner, SM; Holman, R; Horton, ES; Krum, H; Leiter, LA; Mareev, V; McMurray, JJ; Reyes, EM; Schaper, F; Shah, BR; Shen, L; Soska, V; Sun, JL; Thomas, L; Wojdyla, D | 1 |
| Califf, RM; Katz, M; Lopes, RD; McMurray, JJ; Sun, JL; Thomas, L | 1 |
| Bales, CW; Bethel, MA; Califf, RM; Davies, MJ; Haffner, SM; Holman, RR; Huffman, KM; Kraus, WE; McMurray, JJ; Preiss, D; Schulte, PJ; Thomas, L; Tuomilehto, J; Yates, T | 1 |
| Califf, RM; Davies, MJ; Gill, JM; Haffner, SM; Holman, RR; Kraus, WE; McMurray, JJ; Preiss, D; Thomas, LE; Wojdyla, DM; Yates, T | 1 |
| Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL | 1 |
| Bethel, MA; Currie, G; Haffner, SM; Holman, RR; Holzhauer, B; McMurray, JJV | 1 |
| Bethel, M; Boolell, M; Califf, RM; Duggal, A; Haffner, SM; Holman, RR; McMurray, J | 1 |
| Frank, H; Heemann, U; Pscherer, S | 1 |
| Carter, JD; Cole, BK; Keller, SR; Nadler, JL; Nunemaker, CS; Wu, R | 1 |
| Bethel, MA; Califf, RM; Gerlock, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Krum, H; McMurray, JJ; Zuurman, L | 1 |
| Nathan, DM | 1 |
| Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J | 2 |
| Blaak, EE; Diamant, M; Goossens, GH; Hermans, MM; Moors, CC; van der Zijl, NJ | 1 |
| Ichimiya, S; Ikeda, N; Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Ohno, M; Shintani, S; Sone, T; Watarai, M; Yamashita, K | 1 |
| Chow, L; De Gasparo, M; Levens, N | 1 |
11 trial(s) available for valsartan and Glucose Intolerance
| Article | Year |
|---|---|
Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Topics: Antihypertensive Agents; Biomarkers; Cyclohexanes; Diabetes Mellitus; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Potassium; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Atrial Fibrillation; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2013 |
Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Confidence Intervals; Cyclohexanes; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Prevalence; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan; Venous Thromboembolism | 2015 |
Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.
Topics: Body Weight; Cyclohexanes; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Motor Activity; Nateglinide; Phenylalanine; Prospective Studies; Valsartan | 2015 |
Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Creatinine; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Valsartan | 2017 |
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cyclohexanes; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Research Design; Tetrazoles; Valine; Valsartan | 2008 |
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patient Selection; Phenylalanine; Prediabetic State; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan | 2010 |
Effect of valsartan on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.
Topics: Angiotensin Receptor Antagonists; Blood Glucose; Double-Blind Method; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypertension; Japan; Male; Middle Aged; Morbidity; Prospective Studies; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan | 2012 |
8 other study(ies) available for valsartan and Glucose Intolerance
| Article | Year |
|---|---|
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Antihypertensive Agents; Comorbidity; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Predictive Value of Tests; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2013 |
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Models, Statistical; Nateglinide; Phenylalanine; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial.
Topics: Accelerometry; Actigraphy; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cohort Studies; Cyclohexanes; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Middle Aged; Motor Activity; Nateglinide; Phenylalanine; Prospective Studies; Regression Analysis; Risk Factors; Risk Reduction Behavior; Valsartan | 2015 |
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan | 2017 |
Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance.
Topics: Adiponectin; Adult; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Glucose Intolerance; Humans; Insulin Resistance; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Retinol-Binding Proteins, Plasma; Tetrazoles; Valine; Valsartan | 2010 |
Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Gene Expression; Glucose Intolerance; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Macrophages; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mitochondria; Tetrazoles; Valine; Valsartan | 2010 |
Navigating the choices for diabetes prevention.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tetrazoles; Valine; Valsartan | 2010 |
Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Glucose; Blood Pressure; Body Weight; Drug Tolerance; Glucose Intolerance; Hypertension; Insulin Resistance; Lipids; Rats; Rats, Inbred SHR; Tetrazoles; Valine; Valsartan | 1995 |